Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607730 | 1.00 | GID4 (0.61) | GID4HTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL17681818 | 1.00 | GID4 (0.61) | GID4HTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL19358117 | 0.83 | GID4 (0.45) | GID4HTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL30336230 | 0.83 | GID4 (0.45) | GID4HTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL17682379 | 0.83 | GID4 (0.45) | GID4HTR2CHTR2AHTR2BKDM1A | |
| Hydrochloric Acid SCHEMBL17671022 | 0.81 | GID4 (0.44) | GID4HTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL1010830 | 0.80 | PARP1 (0.42) | GID4HTR2CHTR2BPARP10PARP11 | |
| SCHEMBL24548614 | 0.79 | MAOA (0.39) | GID4HTR2CHTR2BMAOADRD2 | |
| SCHEMBL1010578 | 0.79 | HTR2C (0.61) | GID4HTR2CHTR2AHTR2BMAOA | |
| SCHEMBL7993624 | 0.79 | GID4 (0.61) | GID4HTR2CHTR2AMAOADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3993795-B1 | A SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVE AS A D1 POSITIVE ALLOSTERIC MODULATOR | UCB Biopharma SRL (BE) | 2026-04-22 | — | — | EP | disclosed |
| US-12448363-B2 | Kinase inhibitors | VIDYA THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12358890-B2 | Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator | UCB Biopharma SRL (BE) | 2025-07-15 | — | — | US | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | UCB Biopharma SRL (BE) | 2024-02-08 | — | — | US | disclosed |
| EP-4263511-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-2054416-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2011-01-05 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448363-B2 | Kinase inhibitors | BTK, ABL1, LYN | GID4 935/4885HTR2C 1457/4885HTR2A 1804/4885 |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | GID4 3578/4885HTR2C 2712/4885HTR2A 3716/4885 |
| US-12358890-B2 | Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator | OPRD1, ADRA1D, GPR52 | GID4 432/4885HTR2C 66/4885HTR2A 48/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | GID4 3583/4885HTR2C 2742/4885HTR2A 3719/4885 |
| US-20230219923-A1 | KINASE INHIBITORS | BTK, ABL1, LYN | GID4 935/4885HTR2C 1457/4885HTR2A 1804/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | GID4 957/4885HTR2C 65/4885HTR2A 190/4885 |
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | OPRD1, OPRK1, OPRL1 | GID4 803/4885HTR2C 80/4885HTR2A 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.